[go: up one dir, main page]

MX2009011388A - Inhibidores de polimerasa y su uso para el tratamiento de tumores. - Google Patents

Inhibidores de polimerasa y su uso para el tratamiento de tumores.

Info

Publication number
MX2009011388A
MX2009011388A MX2009011388A MX2009011388A MX2009011388A MX 2009011388 A MX2009011388 A MX 2009011388A MX 2009011388 A MX2009011388 A MX 2009011388A MX 2009011388 A MX2009011388 A MX 2009011388A MX 2009011388 A MX2009011388 A MX 2009011388A
Authority
MX
Mexico
Prior art keywords
treatment
tumors
polymerase inhibitors
inhibitors
polymerase
Prior art date
Application number
MX2009011388A
Other languages
English (en)
Inventor
Monika Schaefer-Korting
Hans-Dieter Hoeltje
Original Assignee
Univ Berlin Freie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07090098A external-priority patent/EP1990054A1/de
Application filed by Univ Berlin Freie filed Critical Univ Berlin Freie
Publication of MX2009011388A publication Critical patent/MX2009011388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a inhibidores de polimerasa, en especial inhibidores de polimerasa alfa y su uso en caso de trastornos del crecimiento celular, en especial enfermedades tumorales, con preferencia queratosis actínicas, basaliomas y/o carcinomas espinocelulares.
MX2009011388A 2007-05-11 2008-05-13 Inhibidores de polimerasa y su uso para el tratamiento de tumores. MX2009011388A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP07090098A EP1990054A1 (de) 2007-05-11 2007-05-11 Polymerase-Hemmer und ihre Verwendung zur Behandlung von Tumoren
EP07090106 2007-05-30
EP07075656 2007-07-30
DE102007041968 2007-08-31
EP07075752 2007-09-03
DE102007044849 2007-09-13
EP07075853 2007-09-28
DE102008003477 2008-01-04
PCT/DE2008/000818 WO2008138327A2 (de) 2007-05-11 2008-05-13 Polymerase-hemmer und ihre verwendung zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
MX2009011388A true MX2009011388A (es) 2010-03-30

Family

ID=40002671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011388A MX2009011388A (es) 2007-05-11 2008-05-13 Inhibidores de polimerasa y su uso para el tratamiento de tumores.

Country Status (9)

Country Link
US (1) US20110182973A1 (es)
EP (1) EP2152273A2 (es)
JP (1) JP2010526839A (es)
CN (1) CN101808644A (es)
AU (1) AU2008250809B2 (es)
BR (1) BRPI0810682A2 (es)
CA (1) CA2687007A1 (es)
MX (1) MX2009011388A (es)
WO (1) WO2008138327A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377789B (es) 2012-10-08 2025-03-10 Dow Global Technologies Llc Compuestos de organofosforo para espumas de poliuretano retardantes de llama.
CN105884628B (zh) * 2016-06-06 2018-06-29 上海工程技术大学 2,4-二叔丁基-5-氨基酚的制备方法
EP3516020B1 (en) * 2016-09-20 2022-05-25 LANXESS Corporation Alkylated 3-hydroxydiphenylamine antioxidants
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
US5646155A (en) * 1994-05-12 1997-07-08 University Of Massachusetts Medical Center Drugs to prevent recurrent herpes virus infections
RU2111970C1 (ru) * 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
EA016838B1 (ru) * 2005-06-07 2012-07-30 Йельский Университет Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)

Also Published As

Publication number Publication date
AU2008250809A2 (en) 2010-04-22
AU2008250809A1 (en) 2008-11-20
WO2008138327A9 (de) 2009-12-30
WO2008138327A2 (de) 2008-11-20
BRPI0810682A2 (pt) 2016-11-16
EP2152273A2 (de) 2010-02-17
US20110182973A1 (en) 2011-07-28
JP2010526839A (ja) 2010-08-05
AU2008250809B2 (en) 2010-09-30
CA2687007A1 (en) 2008-11-20
CN101808644A (zh) 2010-08-18
WO2008138327A3 (de) 2009-05-28

Similar Documents

Publication Publication Date Title
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MY147921A (en) Proteasome inhibitors and methods of using the same
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MY192255A (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
UA100540C2 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
PH12015501221A1 (en) Pyrimidinones as pi3k inhibitors
JO3134B1 (ar) مثبطات نشاط akt
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
UA104849C2 (uk) 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
PH12012501372B1 (en) Proteasome inhibitors and methods of using the same
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
MX2012004286A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek.
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
NZ609594A (en) Eph receptor expression in tumor stem cells
EA201170672A1 (ru) Соединения, пригодные для лечения целлюлита
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal